Researchers have unravelled much of the basic molecular biology of cancer and, aided by the outpouring of knowledge that the Human Genome Project has yielded over the past ten years, they have come to understand how the disease progresses.

ECONOMIST: Molecular medicine: Beating cancer | The

Oncology is attractive not only because of the huge need for better drugs but also because that's where the impact of the human genome project has been greatest, yielding targeted drugs such as Genentech's Herceptin for breast cancer and Novartis' Gleevec for chronic myeloid leukemia.

FORBES: Magazine Article